Investor Update

Reminder: Invitation to Roche’s virtual event on key oncology data presented at 2021 ASCO Annual Meeting


We are pleased to invite investors and analysts to participate in our virtual event on Tuesday, 8 June 2021, highlighting Roche data presented during the congress scientific program from June 4 – 8 2021.

16:00 – 17:30 CEST / 15:00 - 16:30 BST
10:00 – 11:30 am EDT / 7:00 – 8:30 am PDT

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 3pm CEST on the day of the event. > click here


  • Early pipeline programs in focus
    William Pao, M.D., Ph.D.,Global Head of Roche Pharma Research and Early Development
    Ira Mellman, Ph.D., Vice President, Cancer Immunology, Genentech Research & Early Development
  • Late-stage pipeline programs in focus
    Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development
  • ASCO 2021 Highlight
    Tecentriq in adjuvant NSCLC: Phase 3 IMpower010 primary results
    Heather Wakelee, M.D., Prof. of Medicine, Stanford University Medical Center / Deputy Director Stanford Cancer Institute
  • Q&A
Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to

A replay of the webcast will be available via >

Best regards,

Karl Mahler
Head of Investor Relations and Roche Group Planning

Sabine Borngräber
Investor Relations Officer
Roche Investor Relations  
Dr. Karl Mahler
Phone: +41 61 68-78503

Jon Kaspar Bayard
Phone: +41 61 68-83894
Dr. Sabine Borngräber
Phone: +41 61 68-88027

Dr. Bruno Eschli
Phone: +41 61 68-75284
Dr. Birgit Masjost
Phone: +41 61 68-84814
Dr. Gerard Tobin
Phone: +41 61 68-72942
Investor Relations North America  
Loren Kalm
Phone: +1 650 225 3217